Weekly HIV Treatment Breakthrough: Theratechnologies' EGRIFTA WR Cuts Injection Volume by 50%

Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy - Theratechnologies (NASDAQ:THTX)

EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the …

Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV®

Weekly HIV Treatment Breakthrough: Theratechnologies' EGRIFTA WR Cuts Injection Volume by 50%

New EGRIFTA WR requires weekly reconstitution vs. daily for EGRIFTA SV, with 50% less injection volume. Patent protected until 2033, available now through specialty pharmacies.